MorphoSys CEO Says Strategy To Build Proprietary Pipeline 'On Track'
Executive Summary
MorphoSys CEO Simon Moroney tells Scrip that sales of Tremfya in the US and now Europe as a treatment for plaque psoriasis will help fund the German biotech's nascent proprietary pipeline.
You may also be interested in...
GSK's Otilimab Goes Head-To-Head To Crack Rheumatoid Arthritis
GlaxoSmithKline is exploring a potential new way of tackling rheumatoid arthritis in just-started Phase III studies which could shake up a disease sector that is already attracting interest from other big pharma companies.
J&J's Guselkumab Nears Crowded EU Psoriasis Market After CHMP OK
Janssen-Cilag/MorphoSys's potential first-in-class psoriasis therapy has received a positive approval recommendation from Europe's top scientific advisory panel, and could become a blockbuster product despite the cluttered and changeable state of the dermatology sector.
MorphoSys Fills Out Pipeline With Xencor Deal
After searching a year and a half for the right compound to complete its proprietary pipeline, German MorphoSys completed a biotech-biotech deal with a simpatico California company.